PLK2

Across TCGA pan-cancer cohorts, PLK2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PLK2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PLK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLK2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

KIRP, DLBC, and OV are the cancer types where PLK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.040	0.912	<.001	36	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
OV	OS	Median	II,III,IV	0.289	0.692	.020	18	view →
BLCA	DFS	Median	III,IV	1.000	0.265	.018	15	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
CESC	DFS	Median	II,III,IV	0.193	0.705	.045	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	OS	Median	All	0.568	0.792	.011	6	view →
LUAD	DFS	Median	II,III,IV	0.205	0.654	.018	3	view →
UCEC	DFS	Median	II,III,IV	0.863	0.436	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PLK2–KIRP (DFS)

Open the KIRP breakdown →